Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04573309 · ClinicalTrials.gov registry record · Phase 2
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04573309: Completed Phase 2 study, sponsored by Alexion Pharmaceuticals.
NCT04573309 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04573309, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
Primary Outcome
Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and was calculated as the average daily copper balance over the collection period.
Interventions
- DRUG ALXN1840
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-07 |
| Est. Completion | 2022-06-07 |
| Phase | Phase 2 |
What the finished NCT04573309 record still lists
NCT04573309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which ALXN1840 is the first listed.
NCT04573309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04573309 about?
NCT04573309 is a clinical study titled "Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840". This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
What is the current status of trial NCT04573309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-09-07. Estimated completion is 2022-06-07.
What interventions are being tested in trial NCT04573309?
The interventions under investigation include: ALXN1840 (DRUG).
Who is sponsoring clinical trial NCT04573309?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04573309's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI